TD Cowen raised the firm’s price target on Johnson & Johnson to $222 from $185 and keeps a Buy rating on the shares. The company reported solid Q3 results and upped its 2025 adjusted operational sales growth guidance, the analyst tells investors in a research note. The firm believes J&J’s announced plans to separate its ortho business should bring 100 basis points of revenue growth and margin improvement to the remaining company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Midday Fly By: Big banks report beats, GM takes $1.6B EV charge
- Johnson & Johnson price target raised to $214 from $190 at UBS
- Morning Movers: Albertsons gains, Goldman falls after quarterly results
- JNJ Earnings: Johnson & Johnson Stock Falls Despite Guidance Boost and Orthopedics Spin-Off Plans